TREACE MEDICAL CONCEPTS Confirms Nasdaq Listing & Public Status

Ticker: TMCI · Form: 8-K · Filed: 2024-01-10T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, public-listing

TL;DR

**TMCI filed a routine 8-K confirming its Nasdaq listing, no new news.**

AI Summary

TREACE MEDICAL CONCEPTS, Inc. filed an 8-K on January 9, 2024, to disclose that it is a publicly traded company with its Common Stock, $0.001 par value per share, listed on The Nasdaq Global Select Market under the trading symbol TMCI. This filing primarily serves to confirm its status as a registrant under the Securities Exchange Act of 1934 and its listing details. For investors, this filing simply reaffirms the company's established public trading status, providing no new material financial or operational information that would immediately impact stock valuation.

Why It Matters

This filing is a routine disclosure confirming TREACE MEDICAL CONCEPTS, Inc.'s public trading status and listing on Nasdaq, providing no new material information for investors.

Risk Assessment

Risk Level: low — This 8-K is a standard administrative filing and does not introduce any new financial or operational risks to the company.

Analyst Insight

This filing is purely administrative and confirms existing public information. A smart investor would recognize there's no new actionable insight here regarding the company's financial performance or strategic direction.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by TREACE MEDICAL CONCEPTS, Inc.?

This 8-K filing, dated January 9, 2024, serves to confirm TREACE MEDICAL CONCEPTS, Inc.'s status as a registrant under the Securities Exchange Act of 1934 and to disclose details about its publicly traded securities, specifically its Common Stock listed on The Nasdaq Global Select Market.

What is the trading symbol for TREACE MEDICAL CONCEPTS, Inc.'s Common Stock?

The trading symbol for TREACE MEDICAL CONCEPTS, Inc.'s Common Stock is TMCI, as stated in the filing under 'Title of each class Trading Symbol(s) Name of each exchange on which registered'.

On which exchange is TREACE MEDICAL CONCEPTS, Inc.'s Common Stock registered?

TREACE MEDICAL CONCEPTS, Inc.'s Common Stock is registered on The Nasdaq Global Select Market, according to the 'Name of each exchange on which registered' section of the filing.

What is the par value per share of TREACE MEDICAL CONCEPTS, Inc.'s Common Stock?

The par value per share of TREACE MEDICAL CONCEPTS, Inc.'s Common Stock is $0.001, as indicated in the filing under 'Common Stock, $0.001 par value per share'.

Does this 8-K filing indicate that TREACE MEDICAL CONCEPTS, Inc. is an emerging growth company?

No, the filing explicitly indicates with a '☐' (unchecked box) next to 'Emerging growth company' that the registrant is not an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-09 18:19:20

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 9, 2024, Treace Medical Concepts, Inc. (the “Company”) posted an investor presentation, which may be accessed through the Company's investor relations website. A copy of the presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Company intends to use this presentation in meetings with analysts, investors and others from time to time, including its presentation by management at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time / 6:45 pm Eastern Time. A live webcast of this event, as well as an archived recording and presentation, will be available in the Investors's section of the Company's website. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Investor Presentation, dated January 9, 2024 (furnished pursuant to Item 7.01) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREACE MEDICAL CONCEPTS, INC. Date: January 9, 2024 By: /s/ Mark L. Hair Mark L. Hair Chief Financial Officer

View on Read The Filing